omadacycline

Omadacycline is a semisynthetic aminomethylcycline antibiotic within the tetracycline class, developed to treat community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI) in adults. It acts as a protein synthesis inhibitor by binding to the 30S ribosomal subunit of bacteria, blocking the binding of aminoacyl-tRNA to the mRNA-ribosome complex, thereby inhibiting protein synthesis. Omadacycline is effective against a broad spectrum of gram-positive and gram-negative bacteria, including strains resistant to other tetracyclines such as methicillin-resistant Staphylococcus aureus (MRSA), penicillin-resistant Streptococcus pneumoniae, Haemophilus influenzae, and Legionella. It can be bacteriostatic or bactericidal depending on the organism involved. Omadacycline was designed to overcome common tetracycline resistance mechanisms like efflux pumps and ribosomal protection proteins[1][3][5][6].

Brand names

Nuzyra

Other names

omadacycline tosylateamadacycline